Noticias y Actividades de Verrica Pharmaceuticals

Verrica Pharmaceuticals es una empresa que cotiza bajo el símbolo de cotización VRCA (US).

Ver el organigrama con sus 15 ejecutivos principales

Biografías más buscadas en Verrica Pharmaceuticals

• Jayson Rieger, Chief Executive Officer
• Lawrence Eichenfield, Director
• Sean Stalfort, Director

Recientes movimientos de ejecutivos en Verrica Pharmaceuticals

• Chris Chapman, se ha incorporado a la empresa como Chief Commercial Officer  (noticia publicada el 12 de febrero de 2026).

Crear su alerta
para seguir los movimientos de los ejecutivos en Verrica Pharmaceuticals.

Verrica Pharmaceuticals tiene 1.913 competidores entre los que se incluyen Sanofi (Francia), Eli Lilly (Estados Unidos) y Moderna (Estados Unidos).

Popular M&A news in Farmacia

• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (publicado el 4 de junio de 2026).
• Contraline acaba de anunciar una recaudación de fondos de 93 millones de dólares. (publicado el 3 de junio de 2026).
• Hims & Hers ha Eucalyptus adquirido (publicado el 2 de junio de 2026).

Otros contactos sugeridos en el sector Farmacia

• Joaquin Duato - Chief Executive Officer and Chairman of the Board en Johnson & Johnson
• Robert Ford - Chief Executive Officer and Chairman of the Board en Abbott
• Jonathan Leff - Director en Larimar Therapeutics

Saber más sobre el sector Farmacia

Últimos comunicados de prensa de Verrica Pharmaceuticals

• Verrica Pharmaceuticals Announces that Development Partner Torii Pharmaceutical Files New Drug Application of TO-208 the Treatment of Molluscum Contagiosum in Japan - Verrica Pharmaceuticals
• Verrica Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Verrica Pharmaceuticals
• Verrica Provides Business and Operational Update - Verrica Pharmaceuticals
• Verrica Pharmaceuticals Announces that Development Partner Torii Pharmaceutical Files New Drug Application of TO-208 the Treatment of Molluscum Contagiosum in Japan - Verrica Pharmaceuticals
• Verrica Announces Pricing of $42.0 Million Public Offering - Verrica Pharmaceuticals
• Press Releases - Verrica Pharmaceuticals
• Verrica Announces Proposed Public Offering - Verrica Pharmaceuticals
• Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership Transition - Verrica Pharmaceuticals
• Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP 315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology Conference - Verrica Pharmaceuticals
• Verrica Pharmaceuticals Announces Restructuring of Commercial Organization - Verrica Pharmaceuticals
• View more press releases Close

Redes sociales sobre Verrica Pharmaceuticals

• Verrica Pharmaceuticals en Wikipedia, Google News y Yahoo Finance
• Verrica Pharmaceuticals en LinkedIn, Twitter y YouTube